AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Finshots Daily
Can Nirma make the jump from suds to pills?
Feb 17, 2024
Explore Nirma's unexpected entry into the pharmaceutical industry, challenges faced in diversifying from detergent to pharma, strategic shift in Indian pharma companies towards API manufacturing, Nirma's potential growth avenues in oncology APIs and CDMO business model.
08:05
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Nirma diversifies into pharma by acquiring Glenmark Life Sciences, aiming to leverage its success and market position.
- Glenmark Life Sciences earns higher margins with a focus on chronic therapies, benefits from domestic manufacturing incentives, and has growth potential in CDMO business.
Deep dives
Nirma's foray into the pharma business
Nirma, a detergent company, has entered the pharmaceutical industry by acquiring a majority stake in Glenmark Life Sciences. Though Nirma's previous attempts to diversify into the pharma and cement industries haven't been as successful, it aims to maintain and grow Glenmark Life Sciences by leveraging its existing success and market position.
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode